At Day 85, patients receiving LFG316 treatment who meet the criteria for a 'responder', will be offered an additional 6 months of LFG316 treatment on a PRN basis. Additional 3 scheduled visits will be attended by LFG316-responder patients during the extension period. However, patients can have unscheduled visits as needed and as determined by the investigator. Safety evaluation and ocular assessments will be performed throughout the study duration.